BioHorizons has near 10% of the global implant market and it...

BioHorizons has near 10% of the global implant market and it will now be reecommending Remplir with them. That's huge product demand.

A little exert from BioHorizons:

"AlloDerm™ RTM is the most widely accepted and researched acellular dermal matrix for dental soft tissue applications. Grafton DBM is a proven bone graft material with clinical success in multiple forms. In 2004, MinerOss®, a mixture of allograft mineralized cortical and cancellous chips, was added to address a wide range of dental bone grafting applications."

They are now selling Remplir instead of Grafton DBM presumably.

Like Paul, I am excited.

Good job you stayed in on half your holdings Hotdog (very nice day on IMU too!)